Brain Safe: Reducing Exposure to Drugs Linked to Alzheimer's
This study will test the efficacy of an application called Brain Safe in reducing older adults' exposure to prescription anticholinergics. Anticholinergics are a class of drugs used to treat many medical problems and have been associated with a higher risk of dementia.
|Minimum Age||Maximum Age||Gender||Healthy Volunteers|
- Primary care visit at Eskenazi Health or Indiana University Health in past year
- At least one prescription for a strong anticholinergic medication in past year and currently using it
- Community-dwelling in Central Indiana
- Not cognitively impaired
- Not terminally ill
- Not sensory impaired (after correction)
- Permanent resident of an extended care facility (nursing home); independent or assisted living is allowed if managing own medication
- Diagnosis of Alzheimer's disease or related dementia or taking dementia medications
- Diagnosis of schizophrenia, bipolar disorder, or schizoaffective disorder
- Involvement in another clinical trial that would prevent or interfere with study objectives
- Sensory or other impairment prohibiting the use of a mobile touchscreen device or other study activity
Participants will be randomly assigned to use either the Brain Safe application or a medication list application for 1 year, with monthly usage reminders. The applications will be loaded on a smartphone provided by the study or the participant.
Brain Safe provides conversation starters for older adults to discuss use of anticholinergics and deprescribing with their doctor. It also includes a medication list, risk calculator, and educational content. The comparison application provides a medication list and information on medications. Investigators will explore the effects of the intervention on reducing use of anticholinergics and improving cognitive function and quality of life.
Dana L Musapatika, MS
Richard John Holden
Richard J Holden, PhD
Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease